Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Leerink Partners Initiates Coverage On Immunocore Hldgs with Outperform Rating, Announces Price Target of $74

Author: Benzinga Newsdesk | April 29, 2024 09:01am
Leerink Partners analyst Jonathan Chang initiates coverage on Immunocore Hldgs (NASDAQ:IMCR) with a Outperform rating and announces Price Target of $74.

Posted In: IMCR

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist